Compare Ascendis Pharma A/S (ASND) vs Five Below Inc (FIVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Five Below Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Five Below Inc trades at $189.77 (market cap $10.47B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals.
| ASND | FIVE | |
|---|---|---|
Market Cap | $17.74B | $10.47B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $247.71 |
52-Week Low | $163.32 | $129.46 |
Enterprise Value | $18.11B | $11.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FIVE trades at $189.39, up 2.8% today, with a bearish technical signal but strong fundamentals including a 36.81% gross margin and 21.13% ROE. Recent earnings beats and a 60% analyst buy rating support momentum, while expansion to 2,000 stores (GlobeNewsWire, July 9, 2026) highlights growth. The stock faces resistance near $191 with net cash flow positive at $152 million in 2025.
Outlook remains positive with a $252.09 consensus target, though risks include margin pressure from 2025's 6.54% net margin and bearish moving averages. Growth drivers are digital marketing and store openings, but investor caution is warranted near technical resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
